← back to search

James Morris

National Laboratory of the Rockies · US
Area of research
Aerospace Engineering · Computational Theory and Mathematics
Research interest
Research interests include Aluminum Alloy Microstructure Properties, Computational Drug Discovery Methods, Microstructure and mechanical properties, and Aluminum Alloys Composites Properties.
h-index
38
citations
6,085
works
284
NIH funding
primary concept
Materials science
email

Recent publications

Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations.
2024cited by 26position: contributordoi
Supplementary Figures S1-S16 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
2024cited by 0position: contributordoi
Table S1 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
2024cited by 0position: contributordoi
Supplementary Figures S1-S16 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
2024cited by 0position: contributordoi
Table S1 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
2024cited by 0position: contributordoi
Table S4 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
2024cited by 0position: contributordoi
Figure 6 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
2024cited by 0position: contributordoi
Table S4 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
2024cited by 0position: contributordoi
Table S6 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
2024cited by 0position: contributordoi
Table S2 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
2024cited by 0position: contributordoi
Table S12 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
2024cited by 0position: contributordoi
Table S7 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
2024cited by 0position: contributordoi
Figure 3 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
2024cited by 0position: contributordoi
Table S9 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
2024cited by 0position: contributordoi
Table S5 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
2024cited by 0position: contributordoi
Table S18 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
2024cited by 0position: contributordoi
Data from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
2024cited by 0position: contributordoi
Table S5 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
2024cited by 0position: contributordoi
Table S12 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
2024cited by 0position: contributordoi
Figure 4 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
2024cited by 0position: contributordoi
Figure 2 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
2024cited by 0position: contributordoi
Figure 3 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
2024cited by 0position: contributordoi
Table S11 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
2024cited by 0position: contributordoi
Table S8 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
2024cited by 0position: contributordoi
Table S9 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
2024cited by 0position: contributordoi
Figure 4 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
2024cited by 0position: contributordoi
Table S3 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
2024cited by 0position: contributordoi
Table S18 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
2024cited by 0position: contributordoi
Figure 6 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
2024cited by 0position: contributordoi
Table S17 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
2024cited by 0position: contributordoi

Grants

Horizontal Gene Transfer at Landscape Scale in Microbial Communities Under Selection For Antimicrobial Resistance
NSF2438081$1,500,0002025–2029PIRePORTER
LTREB: Long Term Studies of Salt Marsh Primary Production
NSF2348767$599,9992024–2029PIRePORTER
Collaborative Research: Extracellular vesicles as vehicles for microbial interactions in marine Black Queen communities
NSF2304067$721,4552023–2027PIRePORTER
Collaborative Research: Quantifying the effects of different nitrogen forms on marsh resilience to environmental change
NSF2203324$234,0222022–2026PIRePORTER
Collaborative Research: Ecology and Evolution of Microbial Interactions in a Changing Ocean
NSF1851085$516,4362019–2024PIRePORTER
RCN-UBE: The Research on STEM Education Network: Improving Research Inclusivity through a Grassroots Culture of Scientific Teaching
NSF1826988$499,4242018–2024PIRePORTER
IEEE Nano Materials & Devices Conference - NMDC-2018 To Be Held In Portland OR, October 14-17, 2018.
NSF1836104$10,0002018–2019PIRePORTER
LTREB Renewal: Long Term Studies of Salt Marsh Primary Production
NSF1654853$539,0002017–2024PIRePORTER
Individual differences in endogenous oxytocin govern social cognition
NSF1657726$499,7732017–2022PIRePORTER
Collaborative Research: Ocean Acidification: Impacts of evolution on the response of phytoplankton populations to rising CO2
NSF1540158$274,3452015–2019PIRePORTER
Collaborative Research: RUI: Human Alteration of Sediment of Delivery to the Coast - Legacies of Land use, Coastal Wetland Accretion, and Future Vulnerability to Sea Level Rise.
NSF1457622$83,1252015–2019PIRePORTER
Collaborative Research: Ocean Acidification: Impacts of evolution on the response of phytoplankton populations to rising CO2
NSF1316101$391,5312013–2015PIRePORTER
NUE: Nano-Science & Engineering: A STE Minor with General Education
NSF1242197$199,0952013–2015PIRePORTER
COLLABORATIVE RESEARCH: SEA-LEVEL RISE AND SALT-MARSH RESPONSE: A PALEO PERSPECTIVE
NSF1322859$62,8762013–2017PIRePORTER
Examining an epigenetic biomarker of social perception
NSF1228522$675,9052012–2016PIRePORTER
LTREB: Long Term Studies of Salt Marsh Primary Production
NSF1052636$450,0002011–2017PIRePORTER
RAPID-Collaborative Research: The Microbial Response to the Gulf Oil Spill: Linking Metabolomes and Metagenomes
NSF1049411$99,8462010–2012PIRePORTER
NSF East Asia Summer Institutes for US Graduate Students
NSF0611772$3,0002006–2007PIRePORTER
LTREB: Long Term Studies of Salt Marsh Primary Production
NSF0316429$300,0002003–2009PIRePORTER
LTREB: Long Term Studies of Salt Marsh Primary Production
NSF9306855$256,3921993–1998PIRePORTER
Computer-Support for Collaborative Writing
NSF9204861$1,009,6611992–1996PIRePORTER
Long-term Ecological Research at North Inlet: Evolution of a Coastal Landscape and Response to Disturbance
NSF9211774$289,5271992–1994PIRePORTER
US-Denmark Cooperative Research: Synthesis of Physio- logically Based Carbon Models for Salt Marsh Ecosystems
NSF8912769$15,2101989–1991PIRePORTER

Frequent collaborators

Howard Lightfoot · Wellcome Sanger Institute2 papers (2020–2022)Mathew J. Garnett · Wellcome Sanger Institute2 papers (2020–2022)Charlotte Tolley · Wellcome/MRC Cambridge Stem Cell Institute2 papers (2020–2022) · 2 papers (2020–2022)Doris M. Rassl · Papworth Hospital NHS Foundation Trust1 papers (2020–2020)Tim Eisen · Cambridge University Hospitals NHS Foundation Trust1 papers (2020–2020)Christopher G. Smith · University of Cambridge1 papers (2020–2020)Nagmi R. Qureshi · Cambridge University Hospitals NHS Foundation Trust1 papers (2020–2020)Viona Rundell · NHS Blood and Transplant1 papers (2020–2020)Nitzan Rosenfeld · Queen Elizabeth Hospital1 papers (2020–2020)Charles Massie · University of Cambridge1 papers (2020–2020)Florent Moulière · Cancer Research UK Manchester Institute1 papers (2020–2020)Davina Gale · AstraZeneca (United Kingdom)1 papers (2020–2020)Karen Howarth · University of Bradford1 papers (2020–2020)Robert C. Rintoul · University of Cambridge1 papers (2020–2020)Jonathan C. M. Wan · The Francis Crick Institute1 papers (2020–2020)Nikolaos Demiris · Cambridge University Hospitals NHS Foundation Trust1 papers (2020–2020)Wendi Qian · Cambridge University Hospitals NHS Foundation Trust1 papers (2020–2020) · 1 papers (2020–2020)Francesco Iorio · University of Perugia1 papers (2020–2020)